The burden of healthcare-associated Clostridium difficile infection in a non-metropolitan setting. Issue 4 (April 2017)

• Record Type: Journal Article
• Authors: Bond, S.E.; Boutlis, C.S.; Yeo, W.W.; Pratt, W.A.B.; Orr, M.E.; Miyakis, S.
• Is Part Of: Journal of hospital infection. Volume 95:Issue 4(2017)
• Page Start: 387
• Page End: 393
• Publication Date: 2017-04
• Subjects: Clostridium difficile infection -- Antimicrobial stewardship programme -- Clinical decision support system -- Healthcare costs -- Length of stay; Cross infection -- Periodicals; Cross infection -- Prevention -- Periodicals; Nosocomial infections -- Periodicals; Nosocomial infections -- Prevention -- Periodicals; Cross Infection -- Periodicals; Cross Infection -- prevention & control -- Periodicals; Infection Control -- Periodicals; Electronic journals; 614.44
• DOI: 10.1016/j.jhin.2016.12.009
• Languages: English
• ISSNs: 0195-6701

Abstract

Summary: Objective: Healthcare-associated Clostridium difficile infection (HCA-CDI) remains a major cause of morbidity and mortality in industrialized countries. However, few data exist on the burden of HCA-CDI in multi-site non-metropolitan settings. This study examined the introduction of an antimicrobial stewardship programme (ASP) in relation to HCA-CDI rates, and the effect of HCA-CDI on length of stay (LOS) and hospital costs. Methods: A comparative before-and-after intervention study of patients aged ≥16 years with HCA-CDI from December 2010 to April 2016 across the nine hospitals of a non-metropolitan health district in New South Wales, Australia was undertaken. The intervention comprised a multi-site ASP supported by a clinical decision support system, with subsequent introduction of email feedback of HCA-CDI cases to admitting medical officers. Main outcome measures: HCA-CDI rates, comparative LOS and hospital costs, prior use of antimicrobials and proton pump inhibitors, and appropriateness of CDI treatment. Results: HCA-CDI rates rose from 3.07 to 4.60 cases per 10, 000 occupied bed-days pre-intervention, and remained stable at 4 cases per 10, 000 occupied bed-days post-intervention ( P = 0.24). Median LOS (17 vs six days; P < 0.01) and hospital costs (AU$19, 222 vs $7861; P < 0.01) were significantly greater for HCA-CDI cases ( N = 91) than for matched controls ( N = 172). Half of the patients with severe HCA-CDI (4/8) did not receive initial appropriate treatment (oral vancomycin). Conclusions: HCA-CDI placed a significant burden on the regional and rural health service through increased LOS and hospital costs. Interventions targeting HCA-CDI could be employed to consolidate the effects of ASPs.